Tesaglitazar

DB06536InvestigationalSmall molecule

Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Tesaglitazar is a proposed treatment for type 2 diabetes and has... Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.

Mechanism: Pharmacologically active on Peroxisome proliferator-activated receptor gamma and Peroxisome proliferator-activated receptor alpha
Curator reviewed
Primary indication: Investigated for use/treatment in diabetes mellitus type 2.Curator reviewed
Formula / weight: C₂₀H₂₄O₇S · 408.465 g/mol (avg)
Code names: AR-H-039242 · AR-H039242XX · AZ-242 · BR-44608

Resolves to

Compound

UNII6734037O3LCAS251565-85-2ChEMBLCHEMBL282686PubChem208901

Structure

InChIKeyCXGTZJYQWSUFET-IBGZPJMESA-NSMILESCCO[C@@H](CC1=CC=C(OCCC2=CC=C(OS(C)(=O)=O)C=C2)C=C1)C(O)=O

Targets

P37231PPARGQ07869PPARA

What you can answer from here — as of August 26, 2024

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tesaglitazar, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account